Q2 FY2026 EarningsQ2 FY26 results were mixed relative to consensus: revenue of $5.15M missed the $5.80M expectation, while gross margin of 57.3% (excluding depreciation) was below the 60.33% mean. However, diluted GAAP EPS of -$0.31 beat the consensus mean of -$0.39, supported by a significant shift toward higher-margin sleep testing services and cost reductions in sales and marketing. Management's pivot to a medical-provider model is gaining traction, with service revenue up 96% YoY, though overall liquidity remains a critical concern with only $1.8M in cash.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Vivos Therapeutics(VVOS) the Revenue is 5.153 M (+34.9%), Miss estimate;the EBIT is -4.825 M (+0.82%), Beat estimate;the EPS is -0.31 (+43.64%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueMiss expectations
0.01B34.90%
0.01B51.83%
-0.00B16.93%
EBITExceed expectations
-0.00B0.82%
-0.01B6.77%
+0.00B7.59%
EPSExceed expectations
-0.3143.64%
-0.3929.09%
+0.080014.55%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf